Quantitative Platelet Disorders

The platelet reference interval is approximately 150 to 450 × 10⁹/L, and thrombocytopenia means a count below the laboratory’s lower reference limit. A count below 100 × 10⁹/L is a separate threshold used in immune thrombocytopenia and several treatment protocols. Clinically significant bleeding is unusual above 50 × 10⁹/L, risk rises progressively below that level, and patients below 10 × 10⁹/L are considered at high risk of spontaneous severe bleeding.^1,2

Mucocutaneous bleeding follows a size-based nomenclature: petechiae measure about 1 mm, purpura about 3 mm, and ecchymoses are 1 cm or larger. The three mechanisms behind a true low count are decreased production, increased destruction or consumption, and abnormal distribution or sequestration. A falsely low count from specimen artifact belongs on the same triage list because it is the one cause the bench resolves.

Confirming the count before classifying it

EDTA-dependent platelet clumping and platelet satellitosis, in which platelets form rosettes around neutrophils, spuriously lower the automated count. Clumps counted as white-cell-sized particles can also raise the WBC count, producing pseudoleukocytosis. Room-temperature-reactive platelet autoantibodies contribute to both phenomena. The blood film is the quality-control step that catches both before an erroneous result is reported: whenever the count contradicts the film, review the film.¹

When pseudothrombocytopenia is suspected, recollect the specimen into a properly filled sodium citrate tube at the nine-parts-blood-to-one-part-anticoagulant ratio, for example 2.7 mL blood plus 0.3 mL citrate. The analyzer runs the citrated specimen normally, but the WBC and platelet counts must be multiplied by 1.1, the reciprocal of the 9/10 dilution. A citrated platelet count of 88 × 10⁹/L therefore reports as 88 × 1.1 = 96.8 × 10⁹/L. All other CBC parameters continue to come from the original EDTA specimen and film.

Decreased production

Congenital causes. Most inherited thrombocytopenias map to specific genes, and platelet size on the film is the fastest route to a short differential.

Fanconi anemia, an inherited bone-marrow-failure syndrome, adds thrombocytopenia with bony or visceral abnormalities and progressing pancytopenia.

Acquired causes. Chemotherapeutic agents such as methotrexate, busulfan, cytarabine, cyclophosphamide, and cisplatin commonly cause dose-limiting marrow hypoplasia. Long-term ethanol use can produce persistent severe thrombocytopenia that resolves within weeks of abstinence, sometimes with a rebound thrombocytosis. Interferon, estrogens, chloramphenicol, tranquilizers, and anticonvulsants can suppress megakaryocytopoiesis; anagrelide suppresses it therapeutically to lower the platelet count in myeloproliferative disease. Megaloblastic anemia causes ineffective thrombopoiesis: the marrow shows increased, dysplastic megakaryocytes, and the platelets that reach circulation are large with possible reduced survival and function. Viruses including CMV, VZV, rubella, EBV, and dengue suppress production, as do bacterial toxins and direct platelet-bacteria interaction; meningococcemia is a common cause of childhood thrombocytopenia. Marrow infiltration by myeloma, lymphoma, metastatic cancer, or fibrosis reduces megakaryocyte numbers directly.¹

Increased destruction and consumption

Immune thrombocytopenia

Current terminology defines immune thrombocytopenia (ITP) by duration: newly diagnosed under 3 months, persistent from 3 to 12 months, and chronic beyond 12 months.⁴

Pediatric ITP peaks at age 2 to 5 and follows an infection or vaccination within the preceding 4 weeks in over half of cases; antibodies or immune complexes raised against the antigen appear to cross-react with the platelet surface. Diagnosis is usually clinical when bleeding onset is recent, the rest of the CBC and examination are normal, and the family history is negative for bleeding disorders. There is no specific confirmatory laboratory test, and most children recover within weeks.¹

Adult ITP is insidious, with fluctuating counts and predominantly mucocutaneous bleeding. Autoantibodies against platelet glycoproteins such as GPIIb/IIIa and GPIa/IIa are found in 50 to 60% of patients and drive splenic and reticuloendothelial clearance. Because megakaryocytes share those glycoproteins, antibody activity adds a production defect. Platelets appear morphologically normal but larger, with an elevated MPV, and the marrow shows megakaryocytic hyperplasia with young forms. HIV and pregnancy complicate the diagnosis; unexplained thrombocytopenia in a high-risk population can signal early HIV disease.^1,2

Immunologic drug-induced thrombocytopenia

Four mechanisms produce drug-dependent immune destruction:

Heparin-induced thrombocytopenia (HIT) is the laboratory-urgent member of this group. Counts typically fall 50% or more from baseline 5 to 10 days after heparin exposure, thrombosis rather than bleeding is the dominant danger, and the 4Ts pattern, which weighs thrombocytopenia depth, timing, thrombosis, and competing causes, sets the pretest probability. Heparin-platelet factor 4 immunoassays screen, serotonin-release assays confirm, and routine platelet transfusion is avoided except for active bleeding or very high bleeding risk. A new thrombocytopenia in a heparin-exposed patient is a flag the laboratory should surface promptly.⁵

Thrombotic microangiopathies

Thrombotic microangiopathy (TMA) combines thrombocytopenia, arteriolar and capillary microthrombi, and microangiopathic hemolytic anemia. The pattern also appears with drugs such as clopidogrel and ticlopidine, transplantation, malignancy, pregnancy, DIC, catastrophic antiphospholipid syndrome, autoimmune disease, HIV, and malignant hypertension.

Thrombotic thrombocytopenic purpura (TTP). The classic pentad adds fever and renal dysfunction to the triad of microangiopathic hemolytic anemia, thrombocytopenia, and neurologic abnormalities, and the two members of the triad are the most consistent findings. Four patterns are recognized: a single acute episode, recurrent disease, drug-induced disease from thienopyridines, and congenital relapsing disease (Upshaw-Shulman syndrome) from autosomal recessive ADAMTS13 mutations. ADAMTS13 normally cleaves ultralarge VWF multimers; its loss allows platelet- and VWF-rich microthrombi to accumulate with little fibrin, red cells fragment under arterial shear, and schistocytes appear on the film.¹

The laboratory picture is a triad of marked thrombocytopenia, polychromasia, and schistocytes with decreased haptoglobin, increased LDH and unconjugated bilirubin, and sometimes hemoglobinuria. The marrow is erythroid-hyperplastic with normal or increased megakaryocytes. PT, PTT, fibrinogen, and D-dimer are usually normal, which separates TTP from DIC. Renal dysfunction occurs in over half of patients but usually without the anuric renal failure of Shiga-toxin-associated HUS.¹

The ISTH diagnostic pathway rests on ADAMTS13 activity measured in a functional assay: activity below 10% defines severe deficiency, an inhibitory autoantibody confirms immune TTP, and testing should never delay treatment in a convincing clinical picture. Because reference-laboratory turnaround can be too slow for acute decisions, the PLASMIC score estimates the pretest probability of severe deficiency from routine results: one point each for a platelet count below 30 × 10⁹/L, hemolysis by reticulocyte count, haptoglobin, or indirect bilirubin, no active cancer, no history of solid-organ or stem-cell transplant, MCV below 90 fL, INR below 1.5, and creatinine below 2 mg/dL. Median scores run about 7 in TTP and 4 to 5 in the mimics, so the score separates TTP from its mimics before the ADAMTS13 result returns.^6,7

Platelet transfusion in TTP is avoided unless there is life-threatening hemorrhage such as intracranial bleeding, because transfused platelets can worsen microthrombosis.

Hemolytic uremic syndrome (HUS). Shiga-toxin-associated HUS follows Shigella dysenteriae or enterohemorrhagic E. coli, especially O157:H7, with bloody diarrhea preceding the triad of hemolytic anemia, renal failure, and mild-to-moderate thrombocytopenia. Shiga toxin damages glomerular endothelium, and urinary findings include red cells, protein, and casts. Complement-mediated HUS often involves complement-regulatory protein variants, and secondary forms follow drugs, transplantation, malignancy, pregnancy, and severe hypertension. Compared with TTP, HUS favors absent neurologic signs, prominent renal dysfunction, and milder fragmentation, but the two are difficult to separate at presentation, and many patients are treated presumptively along the TTP pathway pending ADAMTS13 results.¹

Disseminated intravascular coagulation (DIC). Coagulation activation consumes platelets in intravascular fibrin clots and consumes factors V, VIII, and fibrinogen. Acute DIC produces severe thrombocytopenia, prolonged clotting times, low fibrinogen, and a positive D-dimer; chronic DIC leaves factors near normal with a moderately low platelet count and increased D-dimer or fibrin degradation products, and it can convert to the acute form. The ISTH overt-DIC score combines the platelet count, D-dimer, PT prolongation, and fibrinogen into a single laboratory decision rule for overt DIC, and results must be interpreted with trend and full clinical context.⁸

Purpura fulminans. Large, irregular, blue-black hemorrhages progressing to tissue necrosis mirror DIC in the laboratory: prolonged clotting times, thrombocytopenia, and hypofibrinogenemia. In neonates it suggests severe congenital protein C or S deficiency; in older children and adults, severe sepsis, especially from Neisseria meningitidis, Streptococcus pneumoniae, or group A or B streptococcus, is the important cause.¹

Pregnancy-associated patterns

Gestational thrombocytopenia is the most common cause of thrombocytopenia in pregnancy and is benign once other causes are excluded. Preeclampsia causes thrombocytopenia and can progress to eclampsia, and HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is a severe variant that is difficult to distinguish from TTP, complement-mediated TMA, HUS, and DIC. ITP remains in the differential at childbearing age, and TTP can recur in pregnancy or postpartum.¹

Nonimmune drug and surface effects

Ristocetin, withdrawn from clinical use, agglutinated platelets through VWF-GPIb binding; hematin, protamine sulfate, and bleomycin can interact with platelets directly and cause transient thrombocytopenia.¹

Distribution and dilution

The normal spleen sequesters about one third of the platelet mass, so any splenomegaly, including cirrhosis with portal hypertension, lymphoma, sarcoidosis, and CML, can produce mild thrombocytopenia with a normal total body platelet mass. Hypothermia below about 25 °C during cardiovascular surgery causes transient mild thrombocytopenia and a function defect that reverses on rewarming. Extracorporeal circuits damage and partially activate platelets, occasionally producing severe thrombocytopenia with marked functional impairment. Massive transfusion of stored whole blood dilutes and clears platelets, a rarer problem in the component-therapy era. Mild thrombocytopenia also accompanies chronic renal failure, severe iron deficiency, megaloblastic anemia, and chronic hypoxia.¹

Thrombocytosis

Reactive thrombocytosis produces counts of roughly 450 to 800 × 10⁹/L, occasionally higher, with normal platelet function. Causes include acute blood loss, splenectomy, childbirth, tissue necrosis and surgery, chronic inflammatory disease, infection, exercise, iron deficiency, hemolytic anemia, renal disorders, and malignancy. Production remains responsive to thrombopoietin, the glycoprotein hormone produced mainly by the liver, and the count normalizes as the underlying disorder resolves. Reactive thrombocytosis carries a low complication rate.

Sustained, autonomous thrombocytosis is typical of polycythemia vera, CML, primary myelofibrosis, and essential thrombocythemia (ET). The count alone cannot establish clonality: physical findings, the film, marrow, and the genetic workup are required, and reactive causes must be excluded first. The myeloid neoplasia topic carries the full WHO5 diagnostic criteria for ET.⁹

ET arises from clonal proliferation of a multipotent hematopoietic stem cell and requires a sustained count of at least 450 × 10⁹/L. Three driver mutations account for most cases: JAK2 V617F in about 64%, CALR in about 16%, and MPL W515L/K in about 4%. CALR-mutated ET runs higher platelet counts with roughly half the thrombosis rate of JAK2-mutated disease. Allele burden shapes phenotype: ET typically carries one JAK2 V617F allele and PV carries two, a difference thought to drive transformation risk.

The film can look deceptively benign. Platelets are often normal but can be giant, bizarre, or clumped; micromegakaryocytes and megakaryocyte fragments appear; platelets cluster near the thin edge. Anemia is unusual early, and about a third of patients have mild erythrocytosis that needs separating from polycythemia vera. Marked leukocytosis should prompt reassessment. A platelet count above 400 × 10⁹/L with a significant marrow erythropoietic or granulopoietic increase should prompt reconsideration of PV or PMF, and dyserythropoiesis or dysgranulopoiesis should prompt cytogenetics for del(5q), inv(3), or t(3;3).

Laboratory correlates track the clinical phenotype. Platelets from patients who have thrombosed show increased fibrinogen-binding affinity, elevated thromboxane B2, and elevated β-thromboglobulin, evidence of ongoing in vivo activation. The hemorrhagic phenotype instead correlates with qualitative defects such as deficient epinephrine receptors and granule abnormalities. Aggregation results in ET are variable and nonspecific: epinephrine nonresponse alone does not separate ET from reactive thrombocytosis.

Urgent laboratory patterns

Transfusion support in these situations follows blood banking guidance and the institution’s transfusion service, and the hemostasis procedures behind coagulation testing belong to the hematology testing topics.¹